◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Kymera Therapeutics Inc (KYMR) Net Income 2018–TTM

Name: Kymera Therapeutics Inc (KYMR) net income history 2018-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-19

Kymera Therapeutics Inc annual net income for fiscal TTM was -$299 million, an increase of 3.9% from -$311 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

KYMR Annual Net Income

Net Income (annual)	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31
Net Income	($299M)	($311M)	($224M)	($147M)	($155M)	($100M)	($46M)	($41M)	($21M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

KYMR Quarterly Net Income

Net Income (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Net Income	($61M)	($69M)	($87M)	($82M)	($77M)	($66M)	($71M)	($62M)	($42M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Net Income at Comparable Companies

CORT Net Income — Corcept Therapeutics Incorporated
AXSM Net Income — Axsome Therapeutics Inc
APGE Net Income — Apogee Therapeutics, Inc. Common Stock
KRYS Net Income — Krystal Biotech Inc
CYTK Net Income — Cytokinetics Inc
ARWR Net Income — Arrowhead Pharmaceuticals Inc

More KYMR metrics: Revenue · Gross Profit · Operating Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding

All KYMR financial statements → Interactive KYMR charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.